- The UK Patents Court has determined that one of Boston Scientific's (NYSE:BSX) patents covering the outer seals for transcatheter heart valves that was asserted against Edwards Lifesciences' (EW) SAPIEN 3 valve is invalid, but found that a second patent is valid and infringed.
- Edwards plans to promptly request an appeal on specific aspects of the ruling and believes that it will ultimately prevail. The company says the court's decision does not affect the commercial availability of SAPIEN 3.
- Boston Scientific initiated the litigation which now involves multiple patents in multiple jurisdictions and is expected to take an extended period to resolve.
- Edwards maintains its financial guidance. Shares are off a fraction premarket but only on 100 shares. No premarket trades have been posted for BSX.